Fabio Tucci, PhD
Fabio is currently the chief operating officer at Epigen Biosciences and has over 15 years of experience in drug discovery, medicinal chemistry and organic synthesis. As the Director of Chemistry at Tanabe Research Laboratories, he led the Medicinal Chemistry Department and advanced several programs on inflammation and metabolic diseases to the pipeline of Mitsubishi Tanabe Pharma Corporation in Japan. While at Neurocrine Biosciences, Dr. Tucci served as Principal Scientist in the Medicinal Chemistry Department where he was part of the team that conceived and optimized Elagolix, a potent small-molecule GnRH antagonist that has recently advanced to phase III clinical trials in humans and partnered with Abbott. In addition, he was the lead medicinal chemistry scientist in the melanocortin-4 (MC4) program for obesity and cancer-cachexia and histamine-1 (H1) antagonist for insomnia. Dr. Tucci received a Ph.D. degree in organic chemistry from the Universidade de São Paulo, Brazil, and conducted postdoctoral studies at the University of Wisconsin, Madison and The Scripps Research Institute, La Jolla. He authored/co-authored 62 peer-reviewed publications and is an inventor in 14 patents and patent applications. Dr. Tucci serves in study sections as a reviewer of SBIR and STTR grant applications to the NIH.